Blueprint Medicines Net Worth
Blueprint Medicines Net Worth Breakdown | BPMC |
Blueprint Medicines Net Worth Analysis
Blueprint Medicines' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Blueprint Medicines' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Blueprint Medicines' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Blueprint Medicines' net worth analysis. One common approach is to calculate Blueprint Medicines' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Blueprint Medicines' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Blueprint Medicines' net worth. This approach calculates the present value of Blueprint Medicines' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Blueprint Medicines' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Blueprint Medicines' net worth. This involves comparing Blueprint Medicines' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Blueprint Medicines' net worth relative to its peers.
Enterprise Value |
|
To determine if Blueprint Medicines is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Blueprint Medicines' net worth research are outlined below:
| Blueprint Medicines had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 249.38 M. Net Loss for the year was (506.98 M) with profit before overhead, payroll, taxes, and interest of 177.28 M. | |
| Blueprint Medicines Corp currently holds about 853.11 M in cash with (436.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.28. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Blueprint Medicines Co. to Post Q2 2024 Earnings of Per Share, Zacks Research Forecasts - MarketBeat |
Blueprint Medicines uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Blueprint Medicines Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Blueprint Medicines' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Blueprint Medicines' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Blueprint Medicines is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Blueprint Medicines Corp backward and forwards among themselves. Blueprint Medicines' institutional investor refers to the entity that pools money to purchase Blueprint Medicines' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2023-12-31 | 1.5 M | Lord, Abbett & Co Llc | 2023-12-31 | 1.4 M | Alliancebernstein L.p. | 2023-12-31 | 1.4 M | Geode Capital Management, Llc | 2023-12-31 | 1.3 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.2 M | Goldman Sachs Group Inc | 2023-12-31 | 1.2 M | Polar Capital Holdings Plc | 2023-12-31 | 865 K | Woodline Partners Lp | 2023-12-31 | 814.5 K | American Century Companies Inc | 2023-12-31 | 711.7 K | Blackrock Inc | 2023-12-31 | 6.6 M | Vanguard Group Inc | 2023-12-31 | 6.1 M |
Follow Blueprint Medicines' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.68 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Blueprint Medicines's market, we take the total number of its shares issued and multiply it by Blueprint Medicines's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Project Blueprint Medicines' profitablity
Blueprint Medicines' profitability indicators refer to fundamental financial ratios that showcase Blueprint Medicines' ability to generate income relative to its revenue or operating costs. If, let's say, Blueprint Medicines is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Blueprint Medicines' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Blueprint Medicines' profitability requires more research than a typical breakdown of Blueprint Medicines' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.48) | (0.51) | |
| Return On Capital Employed | (0.58) | (0.61) | |
| Return On Assets | (0.48) | (0.51) | |
| Return On Equity | (3.88) | (3.69) |
When accessing Blueprint Medicines' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Blueprint Medicines' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Blueprint Medicines' profitability and make more informed investment decisions.
The data published in Blueprint Medicines' official financial statements usually reflect Blueprint Medicines' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Blueprint Medicines Corp. For example, before you start analyzing numbers published by Blueprint accountants, it's critical to develop an understanding of what Blueprint Medicines' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Blueprint Medicines' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Blueprint Medicines' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Blueprint Medicines' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Blueprint Medicines Corp. Please utilize our Beneish M Score to check the likelihood of Blueprint Medicines' management manipulating its earnings.
Evaluate Blueprint Medicines' management efficiency
Blueprint Medicines Corp has return on total asset (ROA) of (0.244) % which means that it has lost $0.244 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7953) %, meaning that it created substantial loss on money invested by shareholders. Blueprint Medicines' management efficiency ratios could be used to measure how well Blueprint Medicines manages its routine affairs as well as how well it operates its assets and liabilities. As of May 18, 2024, Return On Tangible Assets is expected to decline to -0.51. In addition to that, Return On Capital Employed is expected to decline to -0.61. At present, Blueprint Medicines' Other Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 613.2 M, whereas Total Assets are forecasted to decline to about 784.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.16 | 2.05 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 2.16 | 2.05 | |
| Enterprise Value Over EBITDA | (13.25) | (12.59) | |
| Price Book Value Ratio | 42.77 | 44.91 | |
| Enterprise Value Multiple | (13.25) | (12.59) | |
| Price Fair Value | 42.77 | 44.91 | |
| Enterprise Value | 2 B | 2.1 B |
The analysis of Blueprint Medicines' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Blueprint Medicines' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Blueprint Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 19.9069 | Revenue 282.2 M | Quarterly Revenue Growth 0.519 | Revenue Per Share 4.632 | Return On Equity (0.80) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Blueprint Medicines insiders, such as employees or executives, is commonly permitted as long as it does not rely on Blueprint Medicines' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Blueprint Medicines insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Blueprint Medicines Corporate Filings
F4 | 17th of May 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 2nd of May 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 10th of April 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 16th of February 2024 Other Reports | ViewVerify |
Blueprint Medicines Earnings per Share Projection vs Actual
Be your own money manager
Our tools can tell you how much better you can do entering a position in Blueprint Medicines without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Blueprint Medicines Corporate Management
Elected by the shareholders, the Blueprint Medicines' board of directors comprises two types of representatives: Blueprint Medicines inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Blueprint. The board's role is to monitor Blueprint Medicines' management team and ensure that shareholders' interests are well served. Blueprint Medicines' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Blueprint Medicines' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alexis AM | CoFounder Director | Profile | |
| JD MBA | Ex Chairman | Profile | |
| Jenna Cohen | Director Relations | Profile | |
| Dr MBA | Chief Officer | Profile | |
| Ariel Hurley | Principal Accounting Officer | Profile | |
| Tracey Esq | Chief VP | Profile |
How to buy Blueprint Stock?
The net worth of Blueprint Medicines Corp is the difference between its total assets and liabilities. Blueprint Medicines' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Blueprint Medicines' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Blueprint Medicines' net worth can be used as a measure of its financial health and stability which can help investors to decide if Blueprint Medicines is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Blueprint Medicines Corp stock.Already Invested in Blueprint Medicines Corp?
The danger of trading Blueprint Medicines Corp is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Blueprint Medicines is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Blueprint Medicines. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Blueprint Medicines Corp is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.82) | Revenue Per Share 4.632 | Quarterly Revenue Growth 0.519 | Return On Assets (0.24) | Return On Equity (0.80) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.